Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of oncology researchers reviewing cancer scans and molecular data, reflecting Ranok Therapeutics’ RNK08954 Phase 1a results and the accelerating race to develop KRAS G12D targeted therapies for pancreatic cancer, lung cancer and other advanced solid tumours.
Pharma & Biotech

Forlong Biotechnology doses first patient in Australian Phase 1 trial of subcutaneous FL115

Forlong Biotechnology begins Australian Phase 1 testing of subcutaneous FL115, targeting lower peak exposure and improved immune activation.

Read More
Pharma & Biotech

Natera’s Signatera Genome separates bladder cancer patients into 91%, 81% and 55% survival groups, but can MRD guide treatment?

Natera reports 91% two-year event-free survival in persistently ctDNA-negative VOLGA patients, strengthening MRD research in bladder cancer.

Read More
A representative image illustrating Teva Pharmaceutical Industries’ ecopipam program as the FDA grants Priority Review for the investigational pediatric Tourette syndrome treatment following positive Phase 3 relapse-prevention data.
Pharma & Biotech

Neurogene reports rapid MECP2 expression and new gene regulation data for NGN-401 in Rett syndrome

Neurogene reports rapid MECP2 expression and new regulation data for NGN-401, strengthening its Rett syndrome research ahead of 2027 results.

Read More
Prime Medicine's PM647 has received FDA clearance to enter first-in-human testing as the company advances a one-time Prime Editing therapy targeting the genetic cause of alpha-1 antitrypsin deficiency. Representative image.
Pharma & Biotech

Dyno Therapeutics reports 152-fold brain transduction improvement and new immune-evasive AAV capsid data at ESGCT 2026

Dyno Therapeutics reports 152-fold higher brain transduction than AAV9 in primates, plus new muscle and antibody-evasive capsid data.

Read More
Pharma & Biotech

Rumi Therapeutics signs option agreement for IND-ready RTX-7340 PDE2 inhibitor in Fragile X syndrome

Rumi Therapeutics secures an option to license RTX-7340 for Fragile X syndrome, with preclinical EEG findings supporting clinical development.

Read More
Representative image: A clinician reviews pancreatic cancer imaging and oncology trial data as Phanes Therapeutics’ spevatamig Phase 2 results highlight the growing role of bispecific antibody research in first-line metastatic pancreatic ductal adenocarcinoma treatment.
Pharma & Biotech

Alterome Therapeutics schedules first Phase 1 clinical data presentation for pan-KRAS inhibitor ALTA3263

Alterome Therapeutics will reveal first ALTA3263 Phase 1 data in November, testing the safety and early activity of its oral pan-KRAS inhibitor.

Read More
Clinical researchers review Phase 3 data for plozasiran after Arrowhead Pharmaceuticals reported substantial triglyceride reductions and fewer acute pancreatitis events in the SHASTA-3 and SHASTA-4 studies. Representative image.
Pharma & Biotech

Arrowhead Pharmaceuticals secures NHS funding recommendation for REDEMPLO in familial chylomicronaemia syndrome

REDEMPLO gains NHS backing for genetically confirmed FCS in England and Wales, following strong triglyceride reductions in the PALISADE trial.

Read More
Representative image illustrating lupus drug research as Beeline Medicines reports promising Phase 2 afimetoran results, highlighting its potential as an oral treatment for systemic lupus erythematosus.
Pharma & Biotech

Afimetoran Phase 2 trial delivers significant lupus improvement as Beeline Medicines eyes pivotal studies

Explore Beeline Medicines' Phase 2 afimetoran lupus results, showing a 30-point response advantage and promising potential for an oral therapy.

Read More
Representative image of babesiosis research and tick-borne infection testing as 60 Degrees Pharmaceuticals reports promising parasite clearance results in patients with relapsing babesiosis treated with tafenoquine-based combination therapy.
Pharma & Biotech

Tafenoquine combinations show promising parasite clearance in immunocompromised patients with babesiosis

60 Degrees Pharmaceuticals reports negative Babesia PCR tests in five patients receiving tafenoquine combinations, with FDA discussions planned.

Read More
Representative image illustrating brain cancer research and targeted radiotherapy as Cerenome prepares to unveil new REYOBIQ clinical trial data evaluating multidose treatment for leptomeningeal metastases, a challenging complication of advanced cancer.
Pharma & Biotech

REYOBIQ brain cancer trial: Cerenome advances targeted radiotherapy ahead of Phase 2 plans

Explore Cerenome's upcoming REYOBIQ brain cancer trial data and what its multidose study could mean for leptomeningeal metastases treatment.

Read More